|
Public Release: 11-May-2015 Japanese Society for Dialysis Therapy to publish ... - EurekAlert (press release) |
 |
 |
|
BioMed Central is pleased to partner with the Japanese Society for Dialysis Therapy in publishing the open access journal Renal Replacement Therapy. The journal will publish its first articles in late 2015.
The journal will be led by Editor-in-Chief, Takashi Shigematsu, Professor and Director of the Division of Nephrology, Department of Internal Medicine at the Wakayama Medical University School of Medicine, Japan. He is also the Director of the Blood Purification Medicine and Clinical Engineering at Wakayama Medical University Hospital. His major research interests focus on bone and mineral metabolism such as chronic kidney disease-related bone and mineral metabolism, involving phosphate metabolism and vitamin D metabolism.
Takashi Shigematsu said: "The number of patients suffering from end-stage renal disease who require renal replacement therapy is increasing worldwide, not only in developed countries but also those that are developing. This is fast becoming a global health issue. With this growing problem, we consider this a good time to share the knowledge about high quality in renal replacement therapy with all. For this reason, we thought it was vital that Renal Replacement Therapy be an open access journal, to remove barriers in the sharing and dissemination of this valuable knowledge."
Renal Replacement Therapy will cover all aspects of hemodialysis, peritoneal dialysis, blood purification, renal transplantation and regenerative medicine. In addition, the journal will accept manuscripts from the fields of chronic kidney disease, acute kidney injury, anemia and iron metabolism, kidney infection, and hypertension. Although affiliated with the Japanese Society for Dialysis Therapy, submissions will be accepted from anywhere in the world.
The Japanese Society for Dialysis Therapy initially will cover all of the article-processing charges for the journal. Professor Kosaku Nitta, president of the society, explained their vision: "We believe that the publication of this journal through BioMed Central will undoubtedly contribute to renal replacement therapy by spreading our knowledge and experience. We hope to see it become one of the top journals of dialysis therapy in the future."
Todd Hummel, Editorial Director for Clinical Medicine at BioMed Central, said: "BioMed Central is glad to welcome the Japanese Society for Dialysis Therapy as one of its publishing partners, and we're looking forward to Renal Replacement Therapy's successful launch. The journal joins our growing portfolio of clinical medicine titles published in partnership with learned societies."
###
Media Contact
Shane Canning
Media Manager
BioMed Central
T: +44 (0)20 3192 2243
M: +44 (0)78 2598 4543
E:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Notes for editors
1. BioMed Central is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector. http://www.biomedcentral.com
|
|
Lagos State Government treats 496 patients for cardiac, renal ailments - The Guardian Nigeria |
|
|
|
 The Lagos State Government says 496 patients had received treatment since the inauguration of the first ultra-modern Cardiac and Renal Centre in West Africa.
Dr Jide Idris, the Commissioner for Health, gave the success profile of the centre recently while highlighting the success health programmes of the state government in four years.
He said that the centre which was inaugurated in March 2015 had contributed tremendously in the reduction of medical tourism.
“We have been able to carry out renal dialysis, cardiac procedures including two heart surgeries and the patients are all doing great.
“Also, Pacemaker insertions have been carried out since the commissioning of the cardiac and renal centre in the state.
“These are treatments many Nigerians travel abroad and spend millions of naira to have these procedures done and it has serious negative impact on the country`s economy, “ he said.
On the Goitre Control programme which was inaugurated on March 17, 2014, the commissioner said that 67 patients had undergone surgery while 62 patients were awaiting surgery.
He also said that 12 patients were currently on medication due to the abnormal thyroid function.
“In the last one year, through the State`s Limb Deformity Corrective Surgery and Rehabilitation Programme, 65 patients were screened and 17 of them were operated upon and referred for physiotherapy.
“One limb corrective surgery had been carried out, two patients were given wheel chair and 23 are awaiting Orthotic devices.
“Our records for the Cleft and Palate Repair Programme, showed 71 patients between the age three-month and 15-years were screened and 48 surgeries were performed.
“31 lips repair, seven palate repairs and 10 nasal repairs were performed in the last one year, “ he said.
Idris said that the state government would also continue to ensure accessible, affordable and quality healthcare for the residents of the state.
|
|
|
Statins May Help Prostate Cancer Patients on ADT - Renal and Urology News |
|
|
May 11, 2015
Prostate cancer remained stable for an average 10 extra months in men taking statins, but more trials are needed to confirm benefits, researchers say.
(HealthDay News) -- Statins may slow the progression of prostate cancer in patients receiving androgen deprivation therapy, according to a study published online in JAMA Oncology.
Among 926 men undergoing androgen deprivation therapy for advanced prostate therapy, those taking statins saw significant benefits, researchers said. Their cancer remained stable for an average of 27.5 months before worsening, compared with an average of 17.4 months among men not taking statins.
"These findings are preliminary, so I would not recommend that everybody start on statins to slow prostate cancer," senior author Philip Kantoff, M.D., chief of solid tumor oncology at the Dana-Farber Cancer Institute in Boston, told HealthDay. Also, Kantoff cautioned that these findings apply only to men who have advanced prostate cancer that has relapsed after androgen deprivation therapy. "This does not speak to early-stage prostate cancer or whether statins are beneficial in preventing prostate cancer," he said.
Patients in the study, conducted from 1996 to 2013, were followed for nearly 6 years on average.
Sources
- Harshman, LC, et al. JAMA Oncol.Published online May 07, 2015. doi:10.1001/jamaoncol.2015.0829.
- Ramos, JD, et al. JAMA Oncol. Published online May 07, 2015. doi:10.1001/jamaoncol.2015.0833.
|
|
Managing Pain in Autosomal Dominant Polycystic Kidney Disease - Renal and Urology News |
|
|
May 12, 2015
Review examines etiology of disease and suggests stepwise approach for pain management.
(HealthDay News) -- The etiology of pain in autosomal dominant polycystic kidney disease is complex, and management of pain should be approached in a stepwise manner, according to a review published in the May issue of The Journal of Urology.
Matthew W. Tellman, from the Indiana University School of Medicine in Indianapolis, and colleagues conducted a systematic literature review of the etiology and management of pain in autosomal dominant polycystic kidney disease and anatomy of renal innervation.
The researchers found that for most patients with autosomal dominant polycystic kidney disease, pain occurs due to renal, hepatic, and mechanical origins. Patients may experience different types of pain complicating confirmation of etiology. Anatomical and histological assessment of renal innervation can help elucidate the mechanisms that can lead to renal pain.
A stepwise approach is recommended for management of pain in autosomal dominant polycystic kidney disease. Due to the high incidence of acute causes of renal pain in autosomal dominant polycystic kidney disease, these must be ruled out first. Non-opioid analgesics and conservative interventions can be used first for chronic pain, before considering opioid analgesics. Surgical interventions such as renal cyst decortication, renal denervation, and nephrectomy can target pain from persistent renal or hepatic cysts.
"Chronic pain in patients with autosomal dominant polycystic kidney disease is often refractory to conservative, medical, and other noninvasive treatments," the authors write.
Source
- Tellman, MW, et al. The Journal of Urology; doi: 10.1016/j.juro.2014.10.124.
|
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
